Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Identifieur interne : 007112 ( Main/Merge ); précédent : 007111; suivant : 007113Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Auteurs : M D Welsh [États-Unis] ; E. Dorflinger ; D. Chernik ; C. WatersSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
English descriptors
- KwdEn :
- Adaptation, Psychological, Adult, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Benzophenones (adverse effects), Benzophenones (therapeutic use), Carbidopa (adverse effects), Carbidopa (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Nitrophenols, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Quality of Life, Sick Role, Sickness Impact Profile, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Benzophenones, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Benzophenones, Carbidopa, Levodopa.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adaptation, Psychological, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Nitrophenols, Quality of Life, Sick Role, Sickness Impact Profile, Treatment Outcome.
Abstract
Research on the impact of disease and treatment on health status and quality of life in patients with movement disorders is limited. We studied quality of life in 46 patients with Parkinson's disease (PD) to determine whether the impact of illness and psychosocial adjustment to illness were improved by 42 days of adjunctive therapy with tolcapone (50 mg, 200 mg, or 400 mg three times a day). This study was conducted in parallel with a double-blind, placebo-controlled, dose-response study of the safety and efficacy of tolcapone in combination with levodopa/carbidopa therapy. Only a subset of individuals from the larger study participated. In the quality of life study, illness impact and adjustment to illness were measured subjectively by the Sickness Impact Profile (SIP) and the Psychosocial Adjustment to Illness Scale-Self-Report (PAIS-SR). Patient ratings of total illness impact (p = 0.003), physical illness impact (p = 0.05), and psychosocial illness impact (p = 0.007) improved significantly in individuals receiving tolcapone compared with those receiving placebo. There was no statistically significant difference in adjustment to illness when the tolcapone and placebo groups were compared; however, 17 of 21 adjustment to illness indicators showed improvement.
PubMed: 10830415
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003F77
- to stream PubMed, to step Curation: 003F77
- to stream PubMed, to step Checkpoint: 003F69
- to stream Ncbi, to step Merge: 000274
- to stream Ncbi, to step Curation: 000274
- to stream Ncbi, to step Checkpoint: 000274
Links to Exploration step
pubmed:10830415Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.</title><author><name sortKey="Welsh, M D" sort="Welsh, M D" uniqKey="Welsh M" first="M D" last="Welsh">M D Welsh</name><affiliation wicri:level="3"><nlm:affiliation>University of Southern California School of Medicine, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Southern California School of Medicine, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dorflinger, E" sort="Dorflinger, E" uniqKey="Dorflinger E" first="E" last="Dorflinger">E. Dorflinger</name></author><author><name sortKey="Chernik, D" sort="Chernik, D" uniqKey="Chernik D" first="D" last="Chernik">D. Chernik</name></author><author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C" last="Waters">C. Waters</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10830415</idno><idno type="pmid">10830415</idno><idno type="wicri:Area/PubMed/Corpus">003F77</idno><idno type="wicri:Area/PubMed/Curation">003F77</idno><idno type="wicri:Area/PubMed/Checkpoint">003F69</idno><idno type="wicri:Area/Ncbi/Merge">000274</idno><idno type="wicri:Area/Ncbi/Curation">000274</idno><idno type="wicri:Area/Ncbi/Checkpoint">000274</idno><idno type="wicri:doubleKey">0885-3185:2000:Welsh M:illness:impact:and</idno><idno type="wicri:Area/Main/Merge">007112</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.</title><author><name sortKey="Welsh, M D" sort="Welsh, M D" uniqKey="Welsh M" first="M D" last="Welsh">M D Welsh</name><affiliation wicri:level="3"><nlm:affiliation>University of Southern California School of Medicine, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Southern California School of Medicine, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dorflinger, E" sort="Dorflinger, E" uniqKey="Dorflinger E" first="E" last="Dorflinger">E. Dorflinger</name></author><author><name sortKey="Chernik, D" sort="Chernik, D" uniqKey="Chernik D" first="D" last="Chernik">D. Chernik</name></author><author><name sortKey="Waters, C" sort="Waters, C" uniqKey="Waters C" first="C" last="Waters">C. Waters</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Psychological</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzophenones (adverse effects)</term><term>Benzophenones (therapeutic use)</term><term>Carbidopa (adverse effects)</term><term>Carbidopa (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nitrophenols</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Quality of Life</term><term>Sick Role</term><term>Sickness Impact Profile</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzophenones</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzophenones</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adaptation, Psychological</term><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nitrophenols</term><term>Quality of Life</term><term>Sick Role</term><term>Sickness Impact Profile</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Research on the impact of disease and treatment on health status and quality of life in patients with movement disorders is limited. We studied quality of life in 46 patients with Parkinson's disease (PD) to determine whether the impact of illness and psychosocial adjustment to illness were improved by 42 days of adjunctive therapy with tolcapone (50 mg, 200 mg, or 400 mg three times a day). This study was conducted in parallel with a double-blind, placebo-controlled, dose-response study of the safety and efficacy of tolcapone in combination with levodopa/carbidopa therapy. Only a subset of individuals from the larger study participated. In the quality of life study, illness impact and adjustment to illness were measured subjectively by the Sickness Impact Profile (SIP) and the Psychosocial Adjustment to Illness Scale-Self-Report (PAIS-SR). Patient ratings of total illness impact (p = 0.003), physical illness impact (p = 0.05), and psychosocial illness impact (p = 0.007) improved significantly in individuals receiving tolcapone compared with those receiving placebo. There was no statistically significant difference in adjustment to illness when the tolcapone and placebo groups were compared; however, 17 of 21 adjustment to illness indicators showed improvement.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007112 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007112 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:10830415
|texte= Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:10830415" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |